Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer

被引:34
|
作者
Zetterlund, Linda Holmstrand [1 ,2 ]
Frisell, Jan [3 ,4 ]
Zouzos, Athanasios [5 ]
Axelsson, Rimma [6 ,7 ]
Hatschek, Thomas [8 ,9 ]
de Boniface, Jana [3 ,10 ]
Celebioglu, Fuat [1 ,2 ]
机构
[1] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden
[2] Soder Sjukhuset, Dept Surg, S-11883 Stockholm, Sweden
[3] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[4] Karolinska Univ Hosp, Dept Breast & Endocrine Surg, S-17176 Stockholm, Sweden
[5] Soder Sjukhuset, Dept Radiol, S-11883 Stockholm, Sweden
[6] Karolinska Inst, Div Radiog, Dept Clin Sci Intervent & Technol, Stockholm, Sweden
[7] Karolinska Univ Hosp Huddinge, Dept Radiol, S-14186 Stockholm, Sweden
[8] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol, S-17176 Stockholm, Sweden
[9] Karolinska Univ Hosp, S-17176 Stockholm, Sweden
[10] Capio St Gorans Hosp, Dept Surg, S-11281 Stockholm, Sweden
关键词
Sentinel lymph node biopsy; Breast cancer; Neoadjuvant systemic therapy; False-negative rate; Identification rate; Node-positive; SURGICAL ADJUVANT BREAST; ACOSOG Z1071 ALLIANCE; RANDOMIZED MULTICENTER; AXILLARY DISSECTION; IDENTIFICATION RATE; CHEMOTHERAPY; DISEASE; SURGERY; LYMPHADENECTOMY; TRASTUZUMAB;
D O I
10.1007/s10549-017-4164-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with clinically node-positive breast cancer planned for neoadjuvant systemic therapy (NAST) may draw advantages from the nodal downstaging effect and reduce the extent of axillary surgery with sentinel lymph node biopsy (SLNB) performed after NAST. Since there are concerns about lower sentinel lymph node (SLN) detection and higher false-negative rates (FNR) in this setting, our aim was to define the accuracy of SLNB after NAST. This Swedish national multicenter trial prospectively recruited 195 breast cancer patients from ten hospitals with T1-T4d biopsy-proven node-positive disease planned for NAST between October 1, 2010 and December 31, 2015. Clinically node-negative axillary status after NAST was not mandatory. SLNB was always attempted and followed by a completion axillary lymph node dissection (ALND). The SLN identification rate was 77.9% (152/195) but improved to 80.7% (138/171) with dual mapping. The median number of SLNs was two (range 1-5). A positive SLNB was found in 52% (79/152), almost 66% (52/79) of whom had additional positive non-sentinel lymph nodes. The overall pathologic nodal response rate was 33.3% (66/195). The overall FNR was 14.1% (13/92) but decreased to 4% (2/50) when only patients with two or more sentinel nodes were analyzed. In biopsy-proven node-positive breast cancer, SLNB after NAST is feasible even though the identification rate is lower than in clinically node-negative patients. Since the overall FNR is unacceptably high, the omission of ALND should only be considered if two or more SLNs are identified.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 50 条
  • [21] Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer
    Park, S.
    Ryu, J. M.
    Paik, H-J
    Yi, H. W.
    Bae, S. Y.
    Lee, S. K.
    Kil, W. H.
    Kim, S. W.
    Lee, J. E.
    Nam, S. J.
    CANCER RESEARCH, 2016, 76
  • [22] Outcome of sentinel lymph node biopsy after neoadjuvant chemotherapy in cytology-proven, node-positive breast cancer
    Choi, H. J.
    Alsharif, E.
    Kim, J. M.
    Ryu, J. M.
    Kim, I.
    Nam, S. J.
    Kim, S. W.
    Yu, J.
    Lee, S. K.
    Lee, J. E.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S69 - S69
  • [23] Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer
    Yagata, Hiroshi
    Yamauchi, Hideko
    Tsugawa, Koichiro
    Hayashi, Naoki
    Yoshida, Atsushi
    Kajiura, Yuka
    In, Reika
    Matsuda, Naoko
    Nakamura, Seigo
    CLINICAL BREAST CANCER, 2013, 13 (06) : 471 - 477
  • [24] Evaluation of axillary response to neoadjuvant systemic therapy with sentinel node biopsy and axillary wire in node-positive breast cancer
    Navarro Sierra, Javier
    Rubio Cuesta, Patricia
    Villalobos Salguero, Francisco Javier
    Espiau Romera, Andrea
    Garcia Mur, Maria del Carmen
    Vicente Gomez, Isabel
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (06) : 1291 - 1299
  • [25] Feasibilty of sentinel lymph node biopsy in patients with node-positive inflammatory breast cancer who responded to neoadjuvant systemic treatment
    Oprea, A. -L.
    Ak, N.
    Saip, P.
    Onder, S.
    Bademler, S.
    Gulluoglu, B. M.
    Karanlik, H.
    BREAST, 2019, 44 : S122 - S123
  • [26] Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy
    Veronesi, Paolo
    Gentilini, Oreste
    Fernandez, Julia Rodriguez
    Magnoni, Francesca
    BREAST, 2009, 18 : S90 - S92
  • [27] Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy
    Veronesi, R.
    Rodriguez, J.
    BREAST, 2009, 18 : S11 - S12
  • [28] Sentinel lymph node biopsy after neoadjuvant systemic therapy
    Mamounas, EP
    SURGICAL CLINICS OF NORTH AMERICA, 2003, 83 (04) : 931 - +
  • [29] Sentinel lymph node biopsy does not apply to all axillary lymph node-positive breast cancer patients after neoadjuvant chemotherapy
    Ge, Wen-kai
    Yang, Ben
    Zuo, Wen-shu
    Zheng, Gang
    Dai, Ying-qi
    Han, Chao
    Yang, Li
    Zheng, Mei-zhu
    THORACIC CANCER, 2014, 5 (06) : 550 - 555
  • [30] is sentinel lymph node (SLN) biopsy really contraindicated in clinically node-positive breast cancerB
    M. Specht
    J. Fey
    P. I. Borgen
    H. S. Cody
    Annals of Surgical Oncology, 2004, 11 : S94 - S94